A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients — Stella

Recruiting

Back to Chronic Spontaneous Urticaria trials

Trial locations(1 site)

United States

Novartis, East Hanover, New Jersey

Key details

Sponsor

Novartis Pharmaceuticals

Enrollment target

~350 participants

Started

January 2026

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 100 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov